Robert M. Davis received $23.2M in total compensation as Chairman Chief Executive Officer and President of Merck & Co., Inc. in FY2024. The largest component was $13.1M in stock awards. That’s up 14% from FY2023. Source: SEC DEF 14A.
Executive Compensation Summary for Merck & Co., Inc.
Robert M. Davis Salary and Compensation - Merck & Co., Inc. CEO Pay 2024
In fiscal year 2024, Robert M. Davis, Chairman Chief Executive Officer and President of Merck & Co., Inc. (MRK), received total compensation of $23.2 million.
Robert M. Davis's compensation breakdown includes: base salary of $1.6 million, stock awards valued at $13.1 million, option awards of $4.7 million, non-equity incentive compensation of $2.8 million, and other compensation of $561K.
Compared to fiscal year 2023, Robert M. Davis's total compensation increased 14% from $20.3 million to $23.2 million.
Merck & Co., Inc. (MRK) Executive Pay 2024
Merck & Co., Inc.'s top 5 named executive officers received combined total compensation of $61.1 million in fiscal year 2024.
The named executive officers disclosed in Merck & Co., Inc.'s 2024 proxy statement are:Robert M. Davis (Chairman Chief Executive Officer and President) with total compensation of $23.2 million, Betty Larson (Executive Vice President and Chief Human Resources Officer) with total compensation of $11.3 million, Dean Li (M.D., Ph.D. Executive Vice President and President, Merck Research Laboratories) with total compensation of $10.1 million, Richard R. DeLuca (Jr. Executive Vice President and President, Merck Animal Health) with total compensation of $9.1 million, and Caroline Litchfield (Executive Vice President and Chief Financial Officer) with total compensation of $7.5 million.